AIIMS: After Lancet’s study hesitation in taking Covaxin jab shouldn’t exist

Sumit Saxena New Delhi, Jan 24 : After the Lancet study, the raging controversy over the efficacy of Covaxin, India’s first indigenous Covid-19 vaccine, should not exist and the fear associated with the vaccination drive should also be put to rest, said Subhasis Panda, Deputy Director (administration), AIIMS, here.
Panda, currently on central deputation, is the first civil services officer to receive the Covaxin jab at AIIMS on Sunday, where he has been working for three years.
He is an IAS officer of the 1997 batch from Himachal Pradesh cadre and served as the Joint Secretary to the government in the Department of Food Civil Supplies.
According to reports, reputed medical journal the Lancet Infectious Diseases on Friday said Covaxin produced tolerable safety outcomes and enhanced immune responses in Phase 1 trials.
Speaking to IANS on this Lancet study, Panda said: “India has developed a safe vaccine. In the backdrop of the Lancet study on Covaxin, the data, statistics and the process of validation has also been approved. Covaxin getting thumbs-up from Lancet is a huge validation.” He added now people should shun apprehensions associated with the vaccination drive.